Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Shanxi
Clinical trial register · China

Clinical Trials in Shanxi, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19212 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:17 UTC
19212
Studies in scope
all four open statuses
11805
Recruiting now
open to new participants
2029
Lead sponsors
across recruiting studies
Top sites
Beijing 5582 Shanghai 3880 Guangzhou 3354 Hangzhou 1824 Wuhan 1342
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5582 Shanghai3880 Guangzhou3354 Hangzhou1824 Wuhan1342
All 625 locations
Target enrolment
to

Trials with a site in Shanxi

18 of 19212 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Brise Pharmaceuticals Co., Ltd.
Phase 2/3
2,079
Shanxi, Inner Mongolia, Beijing, Anhui, Hebei, Jilin City, Hunan, Chongqing
2026-09-30
Not yet open
Brise Pharmaceuticals Co., Ltd.
Phase 3
1,000
Shanxi, Inner Mongolia, Beijing, Anhui, Hebei, Jilin City, Hunan, Chongqing
2026-09-30
Not yet open
Rongchang Pharmaceuticals Co., Ltd.
Phase 1/2
486
Beijing, Hunan, Zhejiang, Shandong, Shanghai, Shanxi, Tianjin
2026-09-15
Recruiting
Phase III Clinical Trial of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
NCT07860216Assessing the Effectiveness of Vaccines in Preventing Adult RSV-caused Lower Respiratory Tract Disease (LRTD)
Beijing BeneWill Technology Development Co., Ltd
Phase 3
25,000
GuiZhou, Hebei, HuBei, HuNan, Shandong, Shanxi, Baoshan
2026-08-21
By invitation
University of Malaya
Not applicable
100
Shanxi
2026-06-05
Active, closed
Xijing Hospital
Observational
1,000
Xian, Shanxi
2026-02-01
Recruiting
Zorifertinib With Osimertinib for NSCLC With Meningeal Progression
NCT07361705Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 1
42
Beijing, Shengyang, Guangzhou, Henan, Shanxi
2026-01-31
Recruiting
Wenzhao Guan
Not applicable
18
Shanxi
2025-05-01
Recruiting
Xijing Hospital of Digestive Diseases
Observational
400
Shanxi
2025-04-30
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
35
Nanchang, Hangzhou, Harbin, Hefei, Jinhua, Nantong, Shanghai, Shanxi
2024-10-09
Active, closed
Xijing Hospital
Not applicable
200
Shanxi
2024-08-30
Recruiting
A Registry Study of Intracranial Atherosclerotic Stenosis Treatment by Intracranial Drug-eluting Stenting in China
NCT05692882Intracranial Arteriosclerosis, Stenosis Artery, Drug-Eluting Stents, Intracranial Artery Stenosis
Sino Medical Sciences Technology Inc.
Not applicable
1,000
Chenzhou, Ganzhou, Jinhua, Ningbo, Shanxi
2023-11-16
Recruiting
Suzhou Abogen Biosciences Co., Ltd.
Phase 1/2
218
Beijing, Guangzhou, Nanning, Shanxi, Shenzhen
2023-09-28
Recruiting
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Genmab
Phase 1/2
952
Beijing, Fujian, Guangdong, Henan, Hubei, Shanxi, Shengyang, Tianjin
2022-12-07
Recruiting
Fudan University
Phase 4
800
Fuzhou, Zhengzhou, Wuhan, Hohhot, Shanghai, Shanxi, Hangzhou, Beijing
2020-01-01
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Janssen Research & Development, LLC
Phase 3
539
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shanxi, Suzhou
2013-09-09
Recruiting
Registry of Multicenter Brain-Heart Comorbidity in China
NCT05961748Ischemic Heart Disease, Cardiac Arrest, Atrial Fibrillation, Heart Failure
Beijing Tiantan Hospital
Observational
100,000
Beijing, Fuzhou, Xiamen, Shenzhen, Harbin, Zhengzhou, Shanghai, Shanxi
2012-01-01
Rows per page Showing 1–18 of 18
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 November 2026. https://priyalifescience.com/clinical-trials-china/city/shanxi

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,212 studies in total at the last sync on 10 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 18 of those studies with a site in Shanxi.

How many clinical trials are recruiting in Shanxi?

12 of the 18 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:17 UTC sync. A further 2 have not yet opened recruitment, 3 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanxi), 18 studies
PhaseStudiesRecruitingShare
Not applicable4222.2%
Observational3216.7%
Phase 1/23216.7%
Phase 33116.7%
Phase 22211.1%
Phase 1115.6%
Phase 2/3115.6%
Phase 4115.6%

Most active sponsors

Lead sponsors with the most studies (Shanxi)
Lead sponsorStudiesRecruiting
Brise Pharmaceuticals Co., Ltd.21
Xijing Hospital20
Alpha Biopharma (Jiangsu) Co., Ltd.11
Beijing BeneWill Technology Development Co., Ltd11
Beijing Tiantan Hospital11
First Affiliated Hospital of Zhejiang University11
Fudan University11
Genmab11
Janssen Research & Development, LLC10
Rongchang Pharmaceuticals Co., Ltd.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.